# Role of Extracellular Matrix in Hypoxic-Ischemic Perinatal White Matter Injury > **NIH NIH R01** · OREGON HEALTH & SCIENCE UNIVERSITY · 2020 · $493,254 ## Abstract Project Summary Progress to treat white matter injury (WMI) in preterm neonates has been hampered by fundamental gaps in the molecular mechanisms of remyelination failure. We seek to promote myelin regeneration by disrupting hyaluronic acid (HA)-mediated signaling that prevents white matter repair and functional plasticity. HA is processed by CNS hyaluronidases to HA fragments (HAf) of varying size. We found that a HAf of ~210 kDa inhibits oligodendrocyte progenitor cell (OPC) maturation in vitro and blocks myelination in vivo. The 210HAf promotes an OPC niche at the expense of myelination by utilizing an AKT-FoxO3 signaling pathway that constrains OPC differentiation. It is our unifying hypothesis that 210HAf blocks myelination through three complementary mechanisms that stimulate OPC proliferation, block preOL maturation and bias microglia to release “anti-inflammatory” factors that constrain OPC differentiation. We will integrate genetic, cellular, and biochemical approaches using a neonatal rat model of hypoxia-ischemia, transgenic mice, primary OPCs and forebrain slice cultures. In aim 1, we will determine a novel CNS role for the tumor suppressor Merlin that regulates OPC proliferation via 210HAf. We will define a pathway downstream of Merlin that promotes OPC proliferation via activation of epidermal growth factor receptor. In aim 2, we found that 210HAf stimulates microglia to release factors associated with “anti- inflammatory” states. We hypothesize that 210HAf promotes microglial release of these factors to disrupt white matter repair by constraining OPC differentiation. We will determine the expression of microglial cytokines stimulated by 210HAf and the HA receptors and signaling pathways involved that may promote an OPC niche. At the conclusion of aim 2, we will undertake in vivo studies to test a broad-spectrum hyaluronidase inhibitor, VCPAL that we have shown promotes myelination after adult WMI. We will determine if VCPAL shifts the balance from factors that promote OPCs toward a state that drives OPC maturation to oligodendrocytes. In aim 3, we will define down-stream targets of the AKT-regulated transcription factor FoxO3 that is chronically activated by 210HAf to constrain OPC maturation. We will define novel mechanisms through which FoxO3 interacts with the chromatin remodeling factor Brg1, which we recently showed regulates OPC specification and differentiation by controlling expression of genes involved in early oligodendrocyte differentiation, like Olig2. We will also define the role of FoxO3 as a molecular marker of human myelination failure to define the window and response to interventions to promote OPC maturation. Our long-term objective is to define molecular mechanisms through which 210HAf signals to regulate WM inflammation and the balance between OPC survival, proliferation and differentiation. A detailed molecular understanding of these closely related processes will provide critically needed insights to develop ... ## Key facts - **NIH application ID:** 9922993 - **Project number:** 5R01NS054044-12 - **Recipient organization:** OREGON HEALTH & SCIENCE UNIVERSITY - **Principal Investigator:** Stephen Arthur Back - **Activity code:** R01 (R01, R21, SBIR, etc.) - **Funding institute:** NIH - **Fiscal year:** 2020 - **Award amount:** $493,254 - **Award type:** 5 - **Project period:** 2006-01-01 → 2022-05-31 ## Primary source NIH RePORTER: https://reporter.nih.gov/project-details/9922993 ## Citation > US National Institutes of Health, RePORTER application 9922993, Role of Extracellular Matrix in Hypoxic-Ischemic Perinatal White Matter Injury (5R01NS054044-12). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9922993. Licensed CC0. --- *[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*